Bioequivalence study of two formulations of lurasidone film coated tablets in healthy subjects under fed conditions

• Published in: Scientific reports Vol. 15; no. 1; pp. 20492 - 8
• Main Authors: Sözer, Gökçe, Nacak, Muradiye, Durucu, Erol, Martin, Wolfgang, Reinsch, Martin, Koru, Selma, Erenmemişoğlu, Aydın
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.07.2025; Nature Portfolio
• Subjects: 631/154/433; 631/154/436; Administration, Oral; Adult; Antipsychotic Agents - administration & dosage; Antipsychotic Agents - pharmacokinetics; Area Under Curve; Bioequivalence; Chromatography, Liquid; Cross-Over Studies; Female; Healthy Volunteers; Humanities and Social Sciences; Humans; Lurasidone; Lurasidone Hydrochloride - administration & dosage; Lurasidone Hydrochloride - pharmacokinetics; Male; Middle Aged; multidisciplinary; Pharmacokinetics; Science; Science (multidisciplinary); Tablets; Tandem Mass Spectrometry; Therapeutic Equivalency; Variation; Young Adult; Lurasidone; Bioequivalence; Pharmacokinetics; Variation
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-025-04800-z

To define the bioequivalence (BE) of two orally administered film coated tablets containing 40 mg lurasidone hydrochloride. A single-dose, open-label, randomized two-way crossover trial was conducted under fed conditions, with a washout period of at least one week. Blood samples were drawn over a period of 72 h and plasma concentrations were analysed using a Liquid Chromatography tandem Mass Spectrometry (LC–MS/MS) method. The Pharmacokinetic (PK) parameters were calculated using Phoenix WinNonlin software, based on non-compartmental analysis. The two one-sided hypothesis at the α = 0.05 level of significance was tested by constructing the 90% confidence interval of two one-sided t-tests for the geometric mean ratios test versus reference preparation with analysis of variance (ANOVA). After oral administration of 40 mg lurasidone hydrochloride under fed conditions, the mean area under the curve (AUC t , AUC ∞ ) and maximum plasma concentrations (C max ) were 175 ng/mL*h; 184 ng/mL*h and 60 ng/mL, respectively for the test product and 185 ng/mL*h; 198 ng/mL*h and 59 ng/mL respectively for the reference product. 90% Confidence Intervals (CI) for all PK parameters were within the acceptance range of 80.00–125.00%. BE was demonstrated between the generic product and the innovator product in healthy Caucasian male subjects. No clinically meaningful differences in safety or tolerability were observed.